KIAA1524
From Wikipedia, the free encyclopedia
KIAA1524
|
|||||||||||
Identifiers | |||||||||||
Symbol(s) | KIAA1524; FLJ12850; MGC163436 | ||||||||||
External IDs | OMIM: 610643 MGI: 2146335 HomoloGene: 10842 | ||||||||||
|
|||||||||||
RNA expression pattern | |||||||||||
Orthologs | |||||||||||
Human | Mouse | ||||||||||
Entrez | 57650 | 224171 | |||||||||
Ensembl | ENSG00000163507 | ENSMUSG00000033031 | |||||||||
Refseq | NM_020890 (mRNA) NP_065941 (protein) |
NM_172616 (mRNA) NP_766204 (protein) |
|||||||||
Location | Chr 3: 109.75 - 109.79 Mb | Chr 16: 48.91 - 48.94 Mb | |||||||||
Pubmed search | [1] | [2] |
KIAA1524, also known as CIP2A, is a human gene.[1]
Protein phosphatase 2A (PP2A) is a cellular tumor suppressor which inhibits cell proliferation and transformation of normal cells to malignant cancer cells. Recent experimental evidence has firmly established that inhibition of PP2A activity is a prerequisite for human cell transformation. However, the in vivo mechanisms by which PP2A activity is inhibited in spontaneously transformed human cancer cells have been unclear.
KIAA1524 gene encodes for a protein (designated Cancerous inhibitor of PP2A (CIP2A)) that was recently demonstrated to inhibit PP2A tumor suppressor activity in human malignancies.[2] More specifically, CIP2A was demonstrated to inhibit PP2A activity towards oncogenic transcription factor c-Myc, and thereby prevent c-Myc proteolytic degradation. Moreover, CIP2A is required for the malignant cellular growth and for in vivo tumor formation. In accordance with the oncogenic role of CIP2A, overexpression of CIP2A promotes Ras-elicited cell growth and transforms immortalized human cells (HEK-TERVs). Thus far overexpression of CIP2A has been demonstrated in three common human malignancies, human head and neck squamous cell carcinoma (HNSCC), colon cancer and gastric cancer.[2][3]
[edit] References
- ^ Entrez Gene: KIAA1524 KIAA1524.
- ^ a b Junttila MR, Puustinen P, Niemelä M, et al (2007). "CIP2A inhibits PP2A in human malignancies". Cell 130 (1): 51–62. doi: . PMID 17632056.
- ^ Soo Hoo L, Zhang JY, Chan EK (2002). "Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer". Oncogene 21 (32): 5006–15. doi: . PMID 12118381.
[edit] Further reading
- Nagase T, Kikuno R, Ishikawa K, et al. (2000). "Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.". DNA Res. 7 (2): 143–50. PMID 10819331.
- Hartley JL, Temple GF, Brasch MA (2001). "DNA cloning using in vitro site-specific recombination.". Genome Res. 10 (11): 1788–95. PMID 11076863.
- Wiemann S, Weil B, Wellenreuther R, et al. (2001). "Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.". Genome Res. 11 (3): 422–35. doi: . PMID 11230166.
- Simpson JC, Wellenreuther R, Poustka A, et al. (2001). "Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing.". EMBO Rep. 1 (3): 287–92. doi: . PMID 11256614.
- Soo Hoo L, Zhang JY, Chan EK (2002). "Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.". Oncogene 21 (32): 5006–15. doi: . PMID 12118381.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi: . PMID 12477932.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi: . PMID 14702039.
- Wiemann S, Arlt D, Huber W, et al. (2004). "From ORFeome to biology: a functional genomics pipeline.". Genome Res. 14 (10B): 2136–44. doi: . PMID 15489336.
- Mehrle A, Rosenfelder H, Schupp I, et al. (2006). "The LIFEdb database in 2006.". Nucleic Acids Res. 34 (Database issue): D415–8. doi: . PMID 16381901.
- Junttila MR, Puustinen P, Niemelä M, et al. (2007). "CIP2A inhibits PP2A in human malignancies.". Cell 130 (1): 51–62. doi: . PMID 17632056.